Evaluation of dynamin 2 knockdown as a therapeutic strategy for RYR1 related myopathy
- 31 March 2025
- journal article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 50, 105339
Abstract
No abstract availableKeywords
Funding Information
- Ionis Pharmaceuticals
- National Institutes of Health (AR078000, CIHR 153056)
This publication has 21 references indexed in Scilit:
- Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypesMolecular Therapy, 2022
- Molecular and cellular basis of genetically inherited skeletal muscle disordersNature Reviews Molecular Cell Biology, 2021
- Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell PhenotypesMolecular Therapy Nucleic Acids, 2019
- Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular DiseaseNeurotherapeutics, 2018
- Congenital myopathies: disorders of excitation–contraction coupling and muscle contractionNature Reviews Neurology, 2018
- The genetics of congenital myopathies2018
- Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in miceNature Communications, 2017
- Increased Expression of Wild-Type or a Centronuclear Myopathy Mutant of Dynamin 2 in Skeletal Muscle of Adult Mice Leads to Structural Defects and Muscle WeaknessThe American Journal of Pathology, 2011
- Mutations in dynamin 2 cause dominant centronuclear myopathyNature Genetics, 2005
- Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum.Journal of Biological Chemistry, 1990